Nanobiotix S.A.

NasdaqGS:NBTX Stock Report

Market Cap: US$1.8b

Nanobiotix Management

Management criteria checks 4/4

Nanobiotix's CEO is Laurent Levy, appointed in Mar 2003, has a tenure of 23.25 years. total yearly compensation is €1.87M, comprised of 24.6% salary and 75.4% bonuses, including company stock and options. directly owns 2.66% of the company’s shares, worth $47.90M. The average tenure of the management team and the board of directors is 6 years and 3.6 years respectively.

Key information

Laurent Levy

Chief executive officer

€1.9m

Total compensation

CEO salary percentage24.58%
CEO tenure23.3yrs
CEO ownership2.7%
Management average tenure6yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 25

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

Summary Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX’s lead indication, head and neck cancer, offers a modeled $624M valuation, but lung cancer programs—despite higher risk—represent two-thirds of the $4.5B risk-adjusted opportunity. JNJ-1900’s platform potential is vast, with even low-probability broad adoption scenarios materially boosting valuation; upcoming clinical milestones in 2026–2027 are pivotal. Current cash runway extends into 2029, reducing near-term financing risk, while the Johnson & Johnson partnership de-risks late-stage development and supports multi-indication expansion. Current development programs target only a fraction of the potential injectable radiotherapy market, leaving substantial long-term platform optionality. Read the full article on Seeking Alpha
Seeking Alpha • Oct 18

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Tuesday said it had reached a final agreement with the European Investment Bank (EIB) to re-align about €30.7M in outstanding debt obligations with its expected development and commercialization timelines. The company had previously announced the agreement-in-principle with the EIB in mid-Sept. As per the newly executed final agreement, NBTX can now defer repayment of the remaining €25.3M of the loan set to be paid in two tranches up to June 2029. The restructuring agreement also includes a new milestone payment of €20M due in June 2029. U.S.-listed shares of NBTX -2.4% to $4 after hours.
Seeking Alpha • Sep 28

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

Nanobiotix press release (NASDAQ:NBTX): 1H GAAP EPS of -€0.76. Revenue of €1.33M (+0.8% Y/Y) beats by €0.11M. Cash and Cash Equivalents: Cash and cash equivalents as of June 30, 2022, were €63.0 million, compared to €83.9 million as of December 31, 2021.
Seeking Alpha • Sep 12

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Monday said it had reached an agreement in principle to restructure €30.7M in outstanding debt obligations related to its 2018 loan agreement with the European Investment Bank. NBTX said the debt restructuring was done to realign debt obligations with the company's development and commercialization timelines. The company said that execution of the amendment to the debt obligations is expected in Q4 2022 after the legal documents are finalized. "Restructuring existing debt obligations to extend the maturity date of the loan will enable Nanobiotix to drive priority development programs in 2023 by extending operating runway an additional quarter," NBTX CFO Bart Van Rhijn said in a statement. NBTX said the restructuring of the debt obligations combined with capital available through its existing equity line allows the company to extend its operating runway into Q1 2024. U.S.-listed shares of NBTX +0.2% to $4.17 in mid-day trading.
Seeking Alpha • Aug 01

French biotech Nanobiotix rebounds to post best ever 47% intraday gain

ADRs of Paris-based clinical-stage biotech Nanobiotix S.A. (NASDAQ:NBTX) recovered from a sharp selloff on Monday to record the biggest ever intraday gain thanks to strong trading volumes. Nanobiotix (NBTX) plunged nearly 30% on above-average volume to reach an all-time low on Friday. However, the stock has added ~47% on Monday, with nearly 34.4K ADRs changing hands compared to the 65-day average of ~1.1K. This quarter, Nanobiotix (NBTX) is on track to launch its first U.S. clinical trial sites in an ongoing pivotal Phase 3 trial for lead candidate NBTXR3 in head and neck squamous cell carcinoma. Its partner for the program, LianBio (LIAN) also plans to activate the first trial site and dose the first patient in Asia in H2 2022 for the candidate against the same indication.

CEO Compensation Analysis

How has Laurent Levy's remuneration changed compared to Nanobiotix's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025€2m€460k

-€24m

Sep 30 2025n/an/a

-€38m

Jun 30 2025n/an/a

-€52m

Mar 31 2025n/an/a

-€60m

Dec 31 2024€2m€460k

-€68m

Sep 30 2024n/an/a

-€51m

Jun 30 2024n/an/a

-€33m

Mar 31 2024n/an/a

-€37m

Dec 31 2023€3m€411k

-€40m

Sep 30 2023n/an/a

-€49m

Jun 30 2023n/an/a

-€59m

Mar 31 2023n/an/a

-€58m

Dec 31 2022€1m€380k

-€57m

Sep 30 2022n/an/a

-€50m

Jun 30 2022n/an/a

-€43m

Mar 31 2022n/an/a

-€45m

Dec 31 2021€4m€380k

-€47m

Sep 30 2021n/an/a

-€45m

Jun 30 2021n/an/a

-€43m

Mar 31 2021n/an/a

-€39m

Dec 31 2020€818k€330k

-€34m

Sep 30 2020n/an/a

-€41m

Jun 30 2020n/an/a

-€48m

Mar 31 2020n/an/a

-€49m

Dec 31 2019€2m€330k

-€51m

Compensation vs Market: Laurent's total compensation ($USD2.14M) is below average for companies of similar size in the US market ($USD5.15M).

Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.

CEO

Laurent Levy (53 yo)

23.3yrs
Tenure
€1,871,792
Compensation

Dr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Dr. Lévy has a thorough understanding of the te...

Leadership Team

NamePositionTenureCompensationOwnership
Laurent Levy
Co-Founder23.3yrs€1.87m2.66%
$ 47.9m
Bart Van Rhijn
Chief Financial & Business Officer and Member of Executive Board5yrs€986.57k0.27%
$ 4.8m
Anne-Juliette Hermant
Chief People Officer & Member of Executive Board6.9yrs€617.77k0.36%
$ 6.5m
Louis Kayitalire
Chief Medical Officer & Member of Executive Board2.8yrs€908.20k0%
$ 0
Earl Bergey
Co-Founder23.4yrsno datano data
Brandon Owens
VP of Strategic Marketing & Corporate Communicationno datano datano data
Margaret Galluzzi
VP & Global Head of Clinical Operations7.4yrsno datano data
Leonard Farber
Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board4.3yrsno datano data
Anne-Sophie Lariviere
Chief Product Innovation & Delivery Officerless than a yearno datano data
6.0yrs
Average Tenure
53yo
Average Age

Experienced Management: NBTX's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Leonard Farber
Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Boardno datano datano data
Enno Spillner
Independent Member of Supervisory Board12yrs€75.00kno data
Gary Phillips
Independent Chairman of Supervisory board5.1yrs€112.50kno data
Silvia Formenti
Member of Scientific Advisory Board3.6yrsno datano data
Robert Ferris
Member of Scientific Advisory Board3.6yrsno datano data
Alain Herrera
Independent Member of Supervisory Board13yrs€60.00kno data
Anne-Marie Graffin
Independent Vice Chairwoman of the Supervisory Board12.5yrs€67.50kno data
Hisham Mehanna
Member of Scientific Advisory Board3.6yrsno datano data
Stephane Champiat
Member of Scientific Advisory Board3.6yrsno datano data
Jean Bourhis
Member of Scientific Advisory Board3.6yrsno datano data
Christophe Tourneau
Member of Scientific Advisory Board3.6yrsno datano data
Nancy Lee
Member of Scientific Advisory Board3.6yrsno datano data
3.6yrs
Average Tenure
62.5yo
Average Age

Experienced Board: NBTX's board of directors are considered experienced (3.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/29 11:02
End of Day Share Price 2026/06/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nanobiotix S.A. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Philippa GardnerEdison Investment Research
Jonathan MillerEvercore ISI
Emmanuel ParotGilbert Dupont